Healthcare / BiotechnologyKOSDAQ
$2700.00
-320.00 (-10.60%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-17.9B · quality 74.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$253.9B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-15.3%
↓Gross Margin
23.7%
↓Debt/Equity
0.14
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-39.7%
FCF CAGR
—
FCF margin
-345.3%
FCF / Net income
1.18x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.57B · net income $-10.48B · FCF $-12.34B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.57B | $3.57B | $7.75B | $12.70B | $16.30B |
| Net Income | $-10.48B | $-10.48B | $-7.67B | $-21.95B | $-20.24B |
| EBITDA | $-7.61B | $-7.61B | $-3.43B | $-18.33B | $-15.58B |
| EPS | -151.00 | -151.00 | -113.75 | -452.49 | -387.25 |
| Gross Margin | 23.7% | 23.7% | 55.8% | 12.9% | 29.9% |
| Operating Margin | -494.6% | -494.6% | -191.6% | -179.3% | -125.1% |
| Net Margin | -293.4% | -293.4% | -99.0% | -172.8% | -124.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.14 | 0.14 | 0.20 | 0.28 | 0.27 |
| Current Ratio | 7.29 | 7.29 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-12.34B | $-12.34B | $-19.58B | $-17.91B | $-19.71B |
| Returns | |||||
| ROE | -15.3% | -15.3% | -17.8% | -45.7% | -41.0% |
| Valuation | |||||
| P/B | 2.73 | 2.73 | 3.26 | 2.25 | 2.88 |
| Growth & Yield | |||||
| Revenue Growth | -53.9% | -53.9% | -39.0% | -22.1% | — |
| EPS Growth | -32.7% | -32.7% | 74.9% | -16.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+37.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-113.75 → -151.00
Residual
+37.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.